M&A Deal Summary

Amgen Acquires Rodeo Therapeutics

On March 30, 2021, Amgen acquired life science company Rodeo Therapeutics for 721M USD

Acquisition Highlights
  • This is Amgen’s 17th transaction in the Life Science sector.
  • This is Amgen’s 12th largest (disclosed) transaction.
  • This is Amgen’s 14th transaction in the United States.
  • This is Amgen’s 2nd transaction in Washington.

M&A Deal Summary
Date 2021-03-30
Target Rodeo Therapeutics
Sector Life Science
Buyer(s) Amgen
Deal Type Add-on Acquisition
Deal Value 721M USD
Advisor(s) Cooley (Legal)

Target

Rodeo Therapeutics

Seattle, Washington, United States
Rodeo Therapeutics is a preclinical-stage biotech company focused on first-in-class small molecule modulators of prostaglandin biology for enhancing tissue repair and regeneration. Rodeo Therapeutics was founded in 2017 and is based in Seattle, Washington.

Search 201,292 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Amgen

Thousand Oaks, California, United States
Category Company
Founded 1980
Sector Life Science
Employees26,700
Revenue 28.2B USD (2023)
DESCRIPTION
Entrance to Amgen's corporate campus in Thousand Oaks, California.
Entrance to Amgen's corporate campus in Thousand Oaks, California.

Amgen is a drug development company focused on discovering, developing, manufacturing and delivering human therapeutics. Amgen uses tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and people's lives. Amgen was founded in 1980 and is based in Thousand Oaks, California.

DEAL STATS #
Overall 18 of 21
Sector (Life Science) 17 of 20
Type (Add-on Acquisition) 17 of 20
State (Washington) 2 of 2
Country (United States) 14 of 16
Year (2021) 2 of 3
Size (of disclosed) 12 of 20
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-03-04 Five Prime Therapeutics

South San Francisco, California, United States

Five Prime Therapeutics, Inc. is a pre-clinical stage biotech company discovering innovative protein and antibody therapeutics. By tackling the tough scientific questions and untapped pathways, we aim to offer new hope by developing novel, breakthrough therapies that have potential to alter the course of disease in cancers with few treatment options. Five Prime Therapeutics was founded in 2001 and is based in South San Francisco, California.

Buy $1.9B
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-07-27 Teneobio

Newark, California, United States

Teneobio is a clinical-stage biotechnology company developing a new class of biologics, Human Heavy-Chain Antibodies (UniAb), for the treatments of cancer, autoimmunity, and infectious diseases. Teneobio's discovery platform, TeneoSeek, comprises genetically engineered animals (UniRat and OmniFlic), next-generation sequencing, bioinformatics, and high-throughput vector assembly technologies. TeneoSeek rapidly identifies large numbers of unique binding molecules specific for therapeutic targets of interest. Versatile antibody variable domains (UniDab) derived from UniAb can be assembled into multi-specific and multivalent therapeutic proteins, surpassing the limitations of conventional antibody therapeutics. Teneobio is based in Newark, California.

Buy $900M
Mergr

Product

Company

Legal